Oncogenic signaling pathways as therapeutic targets in breast cancer
Our laboratory studies oncogene and tumor suppressor induced cancer-specific cellular programs, which cause therapeutic vulnerabilities in breast cancer.
Pharmacological intervention of SARS-CoV-2 entry mechanisms by blockade of TMPRSS activity
The Klefström laboratory has been identifying and developing chemical and pharmacological inhibitors against hepsin/TMPRSS family members for a long time with the goal of preventing cancer invasion. Some of our drugs or drug-like molecules could be repurposed to prevent SARS-CoV-2 entry to cells, potentially offering a fast-track treatment option for the COVID-19 disease.